Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Sold by Great Lakes Advisors LLC

Great Lakes Advisors LLC cut its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 4.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 191,129 shares of the biopharmaceutical company’s stock after selling 8,124 shares during the period. Great Lakes Advisors LLC owned about 0.21% of Ultragenyx Pharmaceutical worth $8,041,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of RARE. Alkeon Capital Management LLC boosted its position in shares of Ultragenyx Pharmaceutical by 34.3% in the 3rd quarter. Alkeon Capital Management LLC now owns 3,011,716 shares of the biopharmaceutical company’s stock valued at $167,301,000 after purchasing an additional 769,884 shares during the period. Baker BROS. Advisors LP lifted its stake in Ultragenyx Pharmaceutical by 7.5% in the third quarter. Baker BROS. Advisors LP now owns 1,576,114 shares of the biopharmaceutical company’s stock valued at $87,553,000 after buying an additional 109,567 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 4.4% in the third quarter. Geode Capital Management LLC now owns 1,571,081 shares of the biopharmaceutical company’s stock valued at $87,296,000 after acquiring an additional 65,623 shares during the period. Two Sigma Advisers LP grew its position in shares of Ultragenyx Pharmaceutical by 123.4% during the third quarter. Two Sigma Advisers LP now owns 987,800 shares of the biopharmaceutical company’s stock worth $54,872,000 after acquiring an additional 545,600 shares during the last quarter. Finally, Point72 Asset Management L.P. increased its holdings in shares of Ultragenyx Pharmaceutical by 35.9% in the 3rd quarter. Point72 Asset Management L.P. now owns 653,660 shares of the biopharmaceutical company’s stock valued at $36,311,000 after acquiring an additional 172,711 shares during the period. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical Stock Down 2.6 %

NASDAQ:RARE opened at $39.25 on Friday. The firm’s fifty day simple moving average is $42.33 and its 200-day simple moving average is $48.25. The stock has a market cap of $3.63 billion, a PE ratio of -6.19 and a beta of 0.67. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $36.87 and a fifty-two week high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The company had revenue of $164.88 million for the quarter, compared to analyst estimates of $163.23 million. Equities analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on RARE. Piper Sandler raised their price objective on shares of Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Monday, January 13th. JPMorgan Chase & Co. dropped their price target on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating on the stock in a research report on Thursday, November 21st. HC Wainwright reaffirmed a “buy” rating and set a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 14th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $118.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 26th. Finally, Wedbush restated a “neutral” rating and set a $48.00 price target (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a research note on Monday, January 13th. One analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $93.50.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CAO Theodore Alan Huizenga sold 967 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $40,710.70. Following the sale, the chief accounting officer now owns 50,265 shares in the company, valued at approximately $2,116,156.50. This represents a 1.89 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider John Richard Pinion sold 14,439 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total value of $607,881.90. Following the transaction, the insider now directly owns 107,766 shares of the company’s stock, valued at $4,536,948.60. The trade was a 11.82 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 136,370 shares of company stock valued at $5,751,499 in the last ninety days. Corporate insiders own 5.80% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.